UBS cuts Telix Pharmaceuticals target price to A$22
UBS cut its target price for Telix Pharmaceuticals by 29% to A$22.00 per share (TLX.AU).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.